Kinpeygo

Kinpeygo is a medicine used to treat adults with primary immunoglobulin A nephropathy (IgAN). IgAN is a disease where the kidneys gradually stop working and eventually fail, requiring patients to undergo dialysis or have a kidney transplant. Kinpeygo is used in people who have at least 1 g of protein in their urine per day or a urine protein-to-creatinine ratio of at least 0.8 g/g (another measure of protein levels in the urine). Kinpeygo is a ‘hybrid medicine’. It is similar to a ‘reference medicine’ containing the same active substance, but is used for a different disease and is given in a different way. The reference medicine for Kinpeygo is Entocort. IgAN is rare, and Kinpeygo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1778](http://www.ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1778). Kinpeygo contains the active substance budesonide.